Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aditxt, Inc. - Common Stock (NQ:ADTX)

1.420 +0.020 (+1.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 54,879
Open 1.400
Bid (Size) 1.390 (30)
Ask (Size) 1.400 (4)
Prev. Close 1.400
Today's Range 1.360 - 1.420
52wk Range 1.340 - 27,200.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
Via Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
Via Investor Brand Network

Performance

YTD
-97.1%
-97.1%
1 Month
-18.9%
-18.9%
3 Month
-85.8%
-85.8%
6 Month
-97.6%
-97.6%
1 Year
-100.0%
-100.0%

More News

Read More
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors
From Aditxt, Inc.
Via Business Wire
Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Terminates Acquisition Agreement with Appili Therapeutics
Via Investor Brand Network
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights ADI-100 Developments in Weekly Update Featuring Leadership Team
Via Investor Brand Network
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™
From Aditxt, Inc.
Via Business Wire
KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
Via Business Wire
KILL Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Mayo Clinic’s Dr. Charles Howe in May 2 Update on ADI-100™ Preclinical Study
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Gains IRB Approval for Endometriosis Diagnostic Study
Via Investor Brand Network
Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025
From Aditxt, Inc.
Via Business Wire
Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Nasdaq Compliance, Hearing Canceled
Via Investor Brand Network
Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
From Aditxt, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Appili CEO in April 4 Update Focused on Infectious Disease Innovation
Via Investor Brand Network
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights CaSe Platform Acquisition in Weekly Update Focused on Early Cancer Detection
Via Investor Brand Network
Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
From Aditxt, Inc.
Via Business Wire
What's going on in today's session
Via Chartmill
These stocks are moving in today's session
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga

Frequently Asked Questions

Is Aditxt, Inc. - Common Stock publicly traded?
Yes, Aditxt, Inc. - Common Stock is publicly traded.
What exchange does Aditxt, Inc. - Common Stock trade on?
Aditxt, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aditxt, Inc. - Common Stock?
The ticker symbol for Aditxt, Inc. - Common Stock is ADTX on the Nasdaq Stock Market
What is the current price of Aditxt, Inc. - Common Stock?
The current price of Aditxt, Inc. - Common Stock is 1.420
When was Aditxt, Inc. - Common Stock last traded?
The last trade of Aditxt, Inc. - Common Stock was at 06/18/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.